SCHEMBL21284735

SCHEMBL21284735

COCCOC(=O)N[C@@H]1CCc2cc(-c3noc(C4CC4)n3)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 6/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ BDKRB1 P46663 4/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ TUBB4A P04350 2/20 0.39
▸ TUBB P07437 2/20 0.39
▸ TUBA3C P0DPH7 2/20 0.39
▸ TUBA1B P68363 2/20 0.39
▸ TUBA4A P68366 2/20 0.39
▸ TUBB4B P68371 2/20 0.39
▸ TUBB3 Q13509 2/20 0.39
▸ TUBB2A Q13885 2/20 0.39
▸ TUBB8 Q3ZCM7 2/20 0.39
▸ TUBA3E Q6PEY2 2/20 0.39
▸ TUBA1A Q71U36 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21284715 0.89 S1PR1 (0.45) S1PR1L3MBTL1BDKRB1CA12CA1
SCHEMBL21284642 0.88 ALDH1A1 (0.43) S1PR1ALDH1A1SMN1; SMN2BDKRB1TSHR
SCHEMBL21284645 0.87 CA12 (0.41) S1PR1BDKRB1CA12CA1CA2
SCHEMBL21284647 0.85 BDKRB1 (0.40) S1PR1BDKRB1CA12CA1CA2
SCHEMBL21178414 0.84 BDKRB1 (0.51) BDKRB1CA12CA1CA2CA9
SCHEMBL21271090 0.83 CA12 (0.49) S1PR1BDKRB1CA12CA1CA2
SCHEMBL21271092 0.83 CA12 (0.49) S1PR1BDKRB1CA12CA1CA2
SCHEMBL21271079 0.82 CA12 (0.46) L3MBTL1BDKRB1CA12CA1CA2
SCHEMBL21271078 0.82 CA12 (0.46) L3MBTL1BDKRB1CA12CA1CA2
SCHEMBL21284749 0.82 CASP3 (0.43) L3MBTL1BDKRB1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740481-B9 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-10-23 — — EP claimed
EP-3740481-B1 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-06-26 — — EP claimed
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-02-20 — — US disclosed
US-12065436-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2024-08-20 — — US disclosed
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2023-04-20 — — US disclosed
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2023-04-20 — — US disclosed
US-11472796-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2022-10-18 — — US disclosed
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-05-20 — — US disclosed
US-10836755-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2020-11-17 — — US disclosed
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2019-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 S1PR1 916/4885ALDH1A1 3390/4885SMN1; SMN2 156/4885
US-10836755-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 S1PR1 916/4885ALDH1A1 3390/4885SMN1; SMN2 156/4885
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 S1PR1 916/4885ALDH1A1 3390/4885SMN1; SMN2 156/4885
US-12065436-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 S1PR1 916/4885ALDH1A1 3390/4885SMN1; SMN2 156/4885
US-11472796-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 S1PR1 916/4885ALDH1A1 3390/4885SMN1; SMN2 156/4885
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 S1PR1 916/4885ALDH1A1 3390/4885SMN1; SMN2 156/4885
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 S1PR1 916/4885ALDH1A1 3390/4885SMN1; SMN2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback